Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles:
Related suggestion:
Top 10 buzzwords in China in 2023Celebrations of Miao New Year and Guzang Festival held in SW China's GuizhouChina registers progress in crackdown on cultural relic crimesHeat tune up for postseason by topping Raptors 118Guardians rally for 3 runs in 10th inning to stun Yankees 8Prince Harry opts for a 'quiet luxury' style in a grey TEmma Bates, a top US contender in the Boston Marathon, will try to beat Kenyans and dodge potholesChina to launch national survey on cultural relicsDunhuang elements shine at fashion weekFine arts students paint beautiful artworks in village in C China's Hubei
1.3549s , 6496.0234375 kb
Copyright © 2024 Powered by Lilly rides Mounjaro, Zepbound to better ,Worldly Wonders news portal